Sign inJoin waitlistJoin the waitlist

Ameen Salahudeen

Assistant Professor · University of Illinois College of Medicine at Chicago

Credentials: · · · · · · · ·

History

University of Illinois College of Medicine at Chicago
Present

Hematology and Medical Oncology
Stanford University. Palo Alto
2017–2020
Internal Medicine
University of Texas Southwestern Medical Center
2014–2017
Stanford University. Palo Alto
2011–2014
Univ of Texas Southwestern Med Sch at Dallas
2007–2011

Research

Organoid Modeling of the Tumor Immune Microenvironment
Cell · 2018 · 1,265 citations
An E3 ligase possessing an iron-responsive hemerythrin domain is a regulator of iron homeostasis
Science · 2009 · First of 8 authors · 348 citations
Progenitor identification and SARS-CoV-2 infection in human distal lung organoids
Nature · 2020 · Co-first of 34 authors · 330 citations

CK
Calvin Kuo
9 papers
Heather Wakelee
4 papers
Tushar Desai
4 papers
Ashiq Masood
3 papers
Regina Stein
3 papers
Arjun Rustagi
2 papers · 2 as a fellow
Catherine Blish
2 papers
Christopher Teran
2 papers
Diane Simeone
2 papers
Everett Vokes
2 papers
Jalees Rehman
2 papers
JS
Janakiraman Subramanian
2 papers

Grants

A Multimodal Approach to Increase Accuracy and Generalizability in Lung Cancer Early Detection
National Cancer Institute · R01
Contact PI · $667.9K · University of Illinois at Chicago
2026–2031
Modeling Oral Cancer in Primary Organoid Culture
National Institute of Dental and Craniofacial Research · K08
Contact PI · $708.2K · University of Illinois at Chicago
2018–2024

Clinical trials

RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer
Principal investigator · Not yet recruiting · Phase 2
University of Illinois at Chicago
2026–2031
The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk
Principal investigator · Recruiting
University of Illinois at Chicago
2026–2029
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2021–2029